Indiana recalls

Siemens ARTIS pheno and ARTIS Icono biplane imaging systems may occasionally display an incorrect, higher x-ray dose reading during patient exams. The actual radiation dose delivered is safe and meets regulatory standards, but the displayed reading can be misleading. This affects certain model numbers used in hospitals and imaging centers.

Zarlengo's Double Dark Chocolate Gelato contains soy lecithin but the label does not list soy as an allergen. This poses a serious risk to people with soy allergies who rely on label information to avoid allergens. The recall affects 1-gallon containers with specific lot codes sold in Illinois, Indiana, and Texas.

Zarlengo's Chocolate Gelato contains soy lecithin but does not clearly list soy as an allergen on the label. This poses a serious risk to people with soy allergies. The recall affects 6 fl oz cups, 16 fl oz cups, 32 fl oz cups, and 1-gallon buckets distributed in Illinois, Indiana, and Texas.

Zarlengo's Chocolate Chocolate Chip Gelato contains soy lecithin but does not label soy as an allergen on the package. This poses a risk to people with soy allergies. The recall affects multiple package sizes (6 fl oz cups, 16 fl oz cups, 32 fl oz cups, 1-gallon and 2-gallon buckets) sold in Illinois, Indiana, and Texas.

Teva Pharmaceuticals is recalling specific batches of Clonidine Transdermal System patches (0.3 mg/day) because they were manufactured using an unapproved raw material that does not meet quality standards. The affected patches were distributed in the U.S. No injuries have been reported.

Teva Pharmaceuticals is recalling specific lots of Clonidine Transdermal System (0.2 mg/day) patches because they were made with an unapproved raw material that does not meet manufacturing standards. Two lots are affected: 100060002 (expires 07/2026) and 100066802 (expires 05/2027). No injuries have been reported.

Teva Pharmaceuticals is recalling certain Clonidine Transdermal System patches (0.1 mg/day) because they were manufactured using an unapproved raw material that does not meet FDA standards. The affected patches were distributed in the U.S. The company and FDA are working to ensure the product is removed from use.

GE Healthcare discovered particles in certain vials of Omnipaque (iohexol), a contrast dye used during medical imaging procedures. The contamination affects 11 specific lot numbers distributed nationwide. No injuries have been reported so far.

GE Healthcare has recalled specific lots of Omnipaque (iohexol) injection, a contrast dye used in medical imaging, because some vials may contain visible particles. This could affect the safety of the procedure if the contaminated solution is used.

Viatris is recalling one lot of Xanax XR (alprazolam) 3 mg extended-release tablets because they failed to meet dissolution specifications—meaning the tablets may not break down and release the medication properly in your body. This affects only lot #8177156 with an expiration date of 02/28/2027, distributed nationwide. No injuries have been reported.

Preferred Pharmaceuticals' Artificial Tears Lubricant Eye Drops in 0.5 oz bottles may not be sterile due to a manufacturing issue. The FDA is recalling specific lots because sterility cannot be assured. No injuries have been reported.

Fagron Compounding Services is recalling specific lots of Vancomycin HCL injections due to two safety concerns: the bags may not be sterile, and a blue plastic part on the administration port could detach during use. The recall affects over 11,600 bags distributed nationwide.

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Fagron Compounding Services is recalling norepinephrine bitartrate injection due to two issues: the sterility of the product cannot be assured, and a blue plastic part on the administration port may detach during use. This medication is used in hospitals and medical facilities to treat critical conditions. Six specific lots distributed nationwide are affected.

Fagron Compounding Services is recalling specific lots of norepinephrine bitartrate injection due to two concerns: the product may not be sterile, and a blue plastic piece on the administration port could detach during use. This medication is used in hospitals and clinical settings to support blood pressure in critically ill patients.

Fresenius Kabi USA is recalling a specific batch of 5% Dextrose Injection due to concerns that the product may not meet sterility standards. This injectable solution is used in medical settings to deliver fluids and glucose to patients. The affected batch (6402165, expiring 05/30/2028) was distributed nationwide.

Fresenius Kabi is recalling specific batches of 5% Dextrose Injection because the company cannot guarantee the product is sterile. This intravenous solution is used in hospitals and medical settings. The affected batches have expiration dates of February 28, 2027.

Fresenius Kabi is recalling a specific batch of 5% Dextrose Injection due to lack of assurance of sterility. The affected product is in 50 mL freeflex bags. This intravenous medication was distributed nationwide, including Alaska and Puerto Rico.

Fresenius Kabi USA is recalling a specific batch of 0.9% Sodium Chloride Injection (a sterile saline solution used in medical settings) because the manufacturer cannot guarantee it remained sterile during production. The affected batch (24EU10010) was distributed nationwide, including Alaska and Puerto Rico.

Fresenius Kabi is recalling specific batches of 0.9% sodium chloride injection (saline) in 1,000 mL freeflex bags due to lack of assurance of sterility. The affected batches were distributed nationwide, including Alaska and Puerto Rico. No injuries have been reported.

Fresenius Kabi is recalling specific batches of 0.9% Sodium Chloride Injection (saline solution) used in medical settings because the manufacturer cannot guarantee the product is sterile. The affected batches were distributed nationwide. No injuries have been reported so far.

Lack of Assurance of Sterility

Fresenius Kabi USA is recalling specific batches of 0.9% Sodium Chloride Injection (a sterile saline solution) because the manufacturer cannot guarantee the product is free from contamination. The affected batches were distributed nationwide, including Alaska and Puerto Rico, between now and June 2027.

Fresenius Kabi USA is recalling specific batches of 0.9% Sodium Chloride Injection (saline) because the manufacturer cannot confirm the product is sterile. Sterility is critical for injectable medications. The affected batches have expiration dates of October 31, 2026, or November 30, 2026.

Fresenius Kabi is recalling specific batches of 0.9% Sodium Chloride Injection due to a lack of assurance that the product is sterile. This injectable solution is used in medical settings and could pose a risk if contaminated. No injuries have been reported to date.

Fresenius Kabi USA is recalling multiple batches of 0.9% Sodium Chloride Injection (saline solution) used for medical purposes because the manufacturer cannot guarantee the product is sterile. The affected batches were distributed nationwide, Alaska, and Puerto Rico. No injuries have been reported.

Fresenius Kabi is recalling specific batches of 0.9% Sodium Chloride Injection (saline) in 100 mL bags due to lack of assurance of sterility. The affected batches were distributed nationwide, including Alaska and Puerto Rico. No injuries have been reported.

Fresenius Kabi is recalling specific batches of 0.9% Sodium Chloride Injection because the manufacturer cannot guarantee these vials are sterile. This injectable medication is used in hospitals and clinical settings. No injuries have been reported.

Fresenius Kabi is recalling one batch of 0.45% sodium chloride injection (saline solution) used in hospitals and medical facilities because the manufacturer cannot guarantee the product is sterile. The affected batch is #6402413 with an expiration date of 02/29/2028. No infections or injuries have been reported so far.